{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:58:38Z","timestamp":1791896318020,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2003,5,23]],"date-time":"2003-05-23T00:00:00Z","timestamp":1053648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,5,23]],"date-time":"2003-05-23T00:00:00Z","timestamp":1053648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2003,6,1]]},"DOI":"10.1038\/sj.leu.2402946","type":"journal-article","created":{"date-parts":[[2003,5,23]],"date-time":"2003-05-23T09:33:03Z","timestamp":1053682383000},"page":"1150-1156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation"],"prefix":"10.1038","volume":"17","author":[{"given":"R","family":"Schots","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Van Riet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Ben Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"De Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Van Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Demanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,5,23]]},"reference":[{"key":"BF2402946_CR1","first-page":"3599","volume":"92","author":"E Carreras","year":"1998","unstructured":"Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599\u20133604.","journal-title":"Blood"},{"key":"BF2402946_CR2","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","volume":"85","author":"SI Bearman","year":"1995","unstructured":"Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005\u20133020.","journal-title":"Blood"},{"key":"BF2402946_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/00007890-199704270-00006","volume":"63","author":"SP Kantrow","year":"1997","unstructured":"Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW . Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation 1997; 63: 1079\u20131086.","journal-title":"Transplantation"},{"key":"BF2402946_CR4","first-page":"177","volume":"18","author":"RA Cahill","year":"1996","unstructured":"Cahill RA, Spitzer TR, Mazumder A . Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant 1996; 18: 177\u2013184.","journal-title":"Bone Marrow Transplant"},{"key":"BF2402946_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.bmt.1701286","volume":"22","author":"R Schots","year":"1998","unstructured":"Schots R, Kaufman L, Van Riet I, Lacor P, Trullemans F, De Waele M et al. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant 1998; 22: 79\u201385.","journal-title":"Bone Marrow Transplant"},{"key":"BF2402946_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","volume":"340","author":"C Gabay","year":"1999","unstructured":"Gabay C, Kushner I . Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448\u2013454.","journal-title":"N Engl J Med"},{"key":"BF2402946_CR7","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/blood.V80.12.2964.2964","volume":"80","author":"JH Antin","year":"1992","unstructured":"Antin JH, Ferrara JL . Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964\u20132968.","journal-title":"Blood"},{"key":"BF2402946_CR8","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.V83.8.2385.2385","volume":"83","author":"L Gugliotta","year":"1994","unstructured":"Gugliotta L, Catani L, Vianelli N, Gherlinzoni F, Miggiano MC, Bandini G et al. High plasma levels of tumor necrosis factor-alpha may be predictive of veno-occlusive disease in bone marrow transplantation. Blood 1994; 83: 2385\u20132386.","journal-title":"Blood"},{"key":"BF2402946_CR9","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.V75.4.1011.1011","volume":"75","author":"E Holler","year":"1990","unstructured":"Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011\u20131016.","journal-title":"Blood"},{"key":"BF2402946_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1600-0609.1997.tb00985.x","volume":"59","author":"M Remberger","year":"1997","unstructured":"Remberger M, Ringden O . Serum levels of cytokines after bone marrow transplantation: increased IL-8 levels during severe veno-occlusive disease of the liver. Eur J Haematol 1997; 59: 254\u2013262.","journal-title":"Eur J Haematol"},{"key":"BF2402946_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/00007890-199209000-00014","volume":"54","author":"FW Symington","year":"1992","unstructured":"Symington FW, Symington BE, Liu PY, Viguet H, Santhanam U, Sehgal PB . The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 1992; 54: 457\u2013462.","journal-title":"Transplantation"},{"key":"BF2402946_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255\u2013267.","journal-title":"Ann Intern Med"},{"key":"BF2402946_CR13","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1097\/00003246-199909000-00016","volume":"27","author":"JG Clark","year":"1999","unstructured":"Clark JG, Madtes DK, Martin TR, Hackman RC, Farrand AL, Crawford SW . Idiopathic pneumonia after bone marrow transplantation: cytokine activation and lipopolysaccharide amplification in the bronchoalveolar compartment. Crit Care Med 1999; 27: 1800\u20131806.","journal-title":"Crit Care Med"},{"key":"BF2402946_CR14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.7326\/0003-4819-109-12-953","volume":"109","author":"ER Gaynor","year":"1988","unstructured":"Gaynor ER, Vitek L, Sticklin L, Creekmore SP, Ferraro ME, Thomas Jr JX et al. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1988; 109: 953\u2013958.","journal-title":"Ann Intern Med"},{"key":"BF2402946_CR15","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.4049\/jimmunol.144.6.2419","volume":"144","author":"LG Thijs","year":"1990","unstructured":"Thijs LG, Hack CE, Strack van Schijndel RJ, Nuijens JH, Wolbink GJ, Eerenberg-Belmer AJ et al. Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J Immunol 1990; 144: 2419\u20132424.","journal-title":"J Immunol"},{"key":"BF2402946_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1600-065X.1985.tb01160.x","volume":"88","author":"R Storb","year":"1985","unstructured":"Storb R, Thomas ED . Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev 1985; 88: 215\u2013238.","journal-title":"Immunol Rev"},{"key":"BF2402946_CR17","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1097\/00007890-200004150-00053","volume":"69","author":"R Schots","year":"2000","unstructured":"Schots R, Trullemans F, Van Riet I, Kaufman L, Hafsia A, Meddeb B et al. The clinical impact of early gram-positive bacteremia and the use of vancomycin after allogeneic bone marrow transplantation. Transplantation 2000; 69: 1511\u20131514.","journal-title":"Transplantation"},{"key":"BF2402946_CR18","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/hep.1840120517","volume":"12","author":"JV Castell","year":"1990","unstructured":"Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC . Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179\u20131186.","journal-title":"Hepatology"},{"key":"BF2402946_CR19","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood.V78.10.2505.2505","volume":"78","author":"G Vachino","year":"1991","unstructured":"Vachino G, Gelfand JA, Atkins MB, Tamerius JD, Demchak P, Mier JW . Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood 1991; 78: 2505\u20132513.","journal-title":"Blood"},{"key":"BF2402946_CR20","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/00007890-200003150-00047","volume":"69","author":"B Charreau","year":"2000","unstructured":"Charreau B, Coupel S, Goret F, Pourcel C, Soulillou JP . Association of glucocorticoids and cyclosporin A or rapamycin prevents E-selectin and IL-8 expression during LPS- and TNFalpha-mediated endothelial cell activation. Transplantation 2000; 69: 945\u2013953.","journal-title":"Transplantation"},{"key":"BF2402946_CR21","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood.V81.12.3458.3458","volume":"81","author":"EM Faioni","year":"1993","unstructured":"Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood 1993; 81: 3458\u20133462.","journal-title":"Blood"},{"key":"BF2402946_CR22","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/sj.bmt.1701445","volume":"22","author":"JH Lee","year":"1998","unstructured":"Lee JH, Lee KH, Kim S, Lee JS, Kim WK, Park CJ et al. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant 1998; 22: 883\u2013888.","journal-title":"Bone Marrow Transplant"},{"key":"BF2402946_CR23","first-page":"471","volume":"11","author":"B Rio","year":"1993","unstructured":"Rio B, Bauduer F, Arrago JP, Zittoun R . N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant 1993; 11: 471\u2013472.","journal-title":"Bone Marrow Transplant"},{"key":"BF2402946_CR24","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/sj.bmt.1702624","volume":"26","author":"S Tanikawa","year":"2000","unstructured":"Tanikawa S, Mori S, Ohhashi K, Akiyama H, Sasaki T, Kaku H et al. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study. Bone Marrow Transplant 2000; 26: 881\u2013886.","journal-title":"Bone Marrow Transplant"},{"key":"BF2402946_CR25","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/sj.bmt.1702821","volume":"27","author":"MW Fried","year":"2001","unstructured":"Fried MW, Duncan A, Soroka S, Connaghan DG, Farrand A, Peter J et al. Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant 2001; 27: 635\u2013639.","journal-title":"Bone Marrow Transplant"},{"key":"BF2402946_CR26","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood.V76.11.2284.2284","volume":"76","author":"VW van Hinsbergh","year":"1990","unstructured":"van Hinsbergh VW, Bauer KA, Kooistra T, Kluft C, Dooijewaard G, Sherman ML et al. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 1990; 76: 2284\u20132289.","journal-title":"Blood"},{"key":"BF2402946_CR27","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood.V89.6.2184","volume":"89","author":"C Salat","year":"1997","unstructured":"Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997; 89: 2184\u20132188.","journal-title":"Blood"},{"key":"BF2402946_CR28","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/0140-6736(93)90416-E","volume":"341","author":"SC Donnelly","year":"1993","unstructured":"Donnelly SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 1993; 341: 643\u2013647.","journal-title":"Lancet"},{"key":"BF2402946_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/15258160050079407","volume":"9","author":"JL Ferrara","year":"2000","unstructured":"Ferrara JL . Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Cell Res 2000; 9: 299\u2013306.","journal-title":"J Hematother Stem Cell Res"},{"key":"BF2402946_CR30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/sj.bmt.1702209","volume":"25","author":"H Khoury","year":"2000","unstructured":"Khoury H, Adkins D, Brown R, Trinkaus K, Vij R, Miller G, Goodnough LT et al. Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity? Bone Marrow Transplant 2000; 25: 737\u2013743.","journal-title":"Bone Marrow Transplant"},{"key":"BF2402946_CR31","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1046\/j.1365-2141.2000.02475.x","volume":"111","author":"R Chopra","year":"2000","unstructured":"Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 1122\u20131129.","journal-title":"Br J Haematol"},{"key":"BF2402946_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJM200103083441001","volume":"344","author":"GR Bernard","year":"2001","unstructured":"Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699\u2013709.","journal-title":"N Engl J Med"},{"key":"BF2402946_CR33","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/sj.bmt.1703306","volume":"28","author":"A Bacigalupo","year":"2001","unstructured":"Bacigalupo A, Oneto R, Lamparelli T, Gualandi F, Bregante S, Raiola AM et al. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant JID-8702459 2001; 28: 1093\u20131096.","journal-title":"Bone Marrow Transplant"},{"key":"BF2402946_CR34","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1182\/blood.V99.8.2712","volume":"99","author":"PA Carpenter","year":"2002","unstructured":"Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002; 99: 2712\u20132719.","journal-title":"Blood"},{"key":"BF2402946_CR35","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1182\/blood.V98.7.2052","volume":"98","author":"HJ Deeg","year":"2001","unstructured":"Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001; 98: 2052\u20132058.","journal-title":"Blood"},{"key":"BF2402946_CR36","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V79.12.3362.bloodjournal79123362","volume":"79","author":"P Herve","year":"1992","unstructured":"Herve P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362\u20133368.","journal-title":"Blood"},{"key":"BF2402946_CR37","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood.V86.3.890.890","volume":"86","author":"E Holler","year":"1995","unstructured":"Holler E, Kolb HJ, Mittermuller J, Kaul M, Ledderose G, Duell T et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995; 86: 890\u2013899.","journal-title":"Blood"},{"key":"BF2402946_CR38","first-page":"988","volume":"18","author":"JC Tse","year":"1998","unstructured":"Tse JC, Moore TB . Monoclonal antibodies in the treatment of steroid-resistant acute graft-versus-host disease. Pharmacotherapy 1998; 18: 988\u20131000.","journal-title":"Pharmacotherapy"},{"key":"BF2402946_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/sj.bmt.1703094","volume":"28","author":"G Kobbe","year":"2001","unstructured":"Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human\/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001; 28: 47\u201349.","journal-title":"Bone Marrow Transplant"},{"key":"BF2402946_CR40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood.V95.1.83","volume":"95","author":"D Przepiorka","year":"2000","unstructured":"Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83\u201389.","journal-title":"Blood"},{"key":"BF2402946_CR41","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.4049\/jimmunol.166.5.3599","volume":"166","author":"A Verbon","year":"2001","unstructured":"Verbon A, Dekkers PE, ten Hove T, Hack CE, Pribble JP, Turner T et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001; 166: 3599\u20133605.","journal-title":"J Immunol"},{"key":"BF2402946_CR42","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood.V90.8.3204","volume":"90","author":"GR Hill","year":"1997","unstructured":"Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL . Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204\u20133213.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2402946.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402946","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402946.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T09:14:25Z","timestamp":1682500465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2402946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,23]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6,1]]}},"alternative-id":["BF2402946"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2402946","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,23]]},"assertion":[{"value":"18 July 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}